Lower-dose blood thinners for people with blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Lungs & breathing clinical trials.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an active blood cancer (such as multiple myeloma, lymphoma, or a related cancer) and are starting or on systemic therapy.
- Your doctor has determined that you have an intermediate or high risk of blood clots (based on a score called Khorana).
- You are receiving one of the study blood thinners at the specific reduced dose or the injection for clot prevention.
- You have not had a major bleed (like in your stomach or brain) in the past month, and you do not have active bleeding right now.
- Your blood counts are adequate (hemoglobin above 8 and platelet count above 30).
- Your kidney and liver function are good enough (no severe kidney or liver disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This trial tests if apixaban, a blood thinner pill, can prevent dangerous blood clots in people with advanced lung cancer who are receiving outpatient chemotherapy or other systemic treatments. It aims to reduce the risk of venous thromboembolism (blood clots in veins) during cancer therapy.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.